ASH 2023 | HAM-Ven as salvage treatment for R/R AML: results from the SAL-RELAX trial
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, presents findings from the SAL-RELAX trial (NCT04330820), evaluating the efficacy of venetoclax in combination with high-dose cytarabine and mitoxantrone (HAM-Ven) as salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML). The trial demonstrates promising results, achieving a complete response (CR) rate of over 80%, even among patients with adverse risk cytogenetics. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pfizer, Novartis, Janssen, BMS, Astellas, AbbVie, Servier
Honoraria: Pfizer, Novartis, Janssen, BMS, Astellas, AbbVie, Servier
Research Funding: Pfizer, Novartis, AbbVie
